Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
In order to focus on developing more lucrative pharmaceutical businesses, Bayer is considering the sale of its diabetes device unit. Optimistically valued at $2.5 billion, the potential sale signals a change in the company’s direction, driven by its relatively new CEO, Marijn Dekkers.
Bayer, headquartered in Leverkusen, Germany, appears to be considering a move that would allow the company to focus on core competencies in the drug development space. In addition to the diabetes unit, other peripheral business units, like the company’s plastics unit, could be placed on the stock market.
The potential deal is only one of many illustrating daring strategy changes that depart from the company’s previous plans, according to a recent Bloomberg article. As recently as January of last year, the previous CEO Joerg Reinhardt claimed that the company had no plans to sell the diabetes unit. Some observers believe that this move makes sense, although there could be challenges.
http://www.meddeviceonline.com/doc/bayer-exploring-sale-of-billion-diabetes-device-business-0001
Bayer, headquartered in Leverkusen, Germany, appears to be considering a move that would allow the company to focus on core competencies in the drug development space. In addition to the diabetes unit, other peripheral business units, like the company’s plastics unit, could be placed on the stock market.
The potential deal is only one of many illustrating daring strategy changes that depart from the company’s previous plans, according to a recent Bloomberg article. As recently as January of last year, the previous CEO Joerg Reinhardt claimed that the company had no plans to sell the diabetes unit. Some observers believe that this move makes sense, although there could be challenges.
http://www.meddeviceonline.com/doc/bayer-exploring-sale-of-billion-diabetes-device-business-0001